Goldman Sachs Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $139
Truist Financial Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $90
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BioMarin Pharmaceutical Projects Strong Growth Through 2034
Express News | Biomarin Pharmaceutical Inc: Reaffirming Its Long-Term Financial Guidance and Outlook That It Presented During Investor Day
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC Speakers
Citi Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $93
Citi analyst David Lebowitz maintains $Biomarin Pharmaceutical(BMRN.US)$ with a hold rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate of 52.9%
Wells Fargo Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $90
Wells Fargo analyst Derek Archila initiates coverage on $Biomarin Pharmaceutical(BMRN.US)$ with a buy rating, and sets the target price at $90.According to TipRanks data, the analyst has a success
Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $110
Barclays analyst Gena Wang maintains $Biomarin Pharmaceutical(BMRN.US)$ with a buy rating, and maintains the target price at $110.According to TipRanks data, the analyst has a success rate of 44.9%
Barclays Remains a Buy on BioMarin Pharmaceutical (BMRN)
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Maintains Target Price $93
CCORF analyst Whitney Ijem maintains $Biomarin Pharmaceutical(BMRN.US)$ with a hold rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate of 51.3%
A Quick Look at Today's Ratings for Biomarin Pharmaceutical(BMRN.US), With a Forecast Between $72 to $115
On Sep 18, major Wall Street analysts update their ratings for $Biomarin Pharmaceutical(BMRN.US)$, with price targets ranging from $72 to $115.Barclays analyst Gena Wang maintains with a buy rating,
Hold Rating on BioMarin Pharmaceutical Amid Competitive Dynamics and Market Penetration Nuances for Voxzogo
BioMarin To Present Positive VOXZOGO (Vosoritide) Data From CANOPY Clinical Program At 2024 International Skeletal Dysplasia Society Meeting
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO (Vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children With Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
BioMarin Pharmaceutical Price Target Cut to $90.00/Share From $115.00 by Wells Fargo
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday